The third quarter of 2019 has been historical for European listed biotechs. The total amounts raised or secured by the 150+ listed companies under coverage reached 2168 mEUR, all categories included (equity issue, US IPO, warrants/equity lines, debt/non-dilutive sources). That makes this quarter likely the best ever… However, this number hides a much less positive[…]